search
Back to results

Medication and Counseling for Controlled Drinking (Project SMART)

Primary Purpose

Alcohol-related Disorders, Alcohol Drinking, Alcoholism

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Naltrexone
Modified Behavioral Self-Control Psychotherapy
Brief Behavioral Compliance Enhancement Therapy
Sponsored by
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol-related Disorders focused on measuring Drinking, Alcohol problems, Alcoholism, Gay men, Bisexual men, Moderation-oriented treatment, Controlled drinking, Non-abstinence based treatment

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Males 18-65 years old
  • Currently sexually active with other men
  • Report drinking at levels substantially in excess of established guidelines for non-hazardous drinking
  • Willing to reduce drinking to non-hazardous levels
  • English literate (8th grade level)

Exclusion Criteria:

  • Current physical disease or condition making participant inappropriate for a medication trial, including total bilirubin elevation >110%, AST or ALT elevations >300%.
  • History of serious psychiatric illness (psychotic disorder, bipolar disorder, or psychiatric illness requiring hospitalization), current psychiatric illness (such as major depression or post-traumatic stress disorder) that requires treatment but that is currently untreated, or serious risk of suicidal or violent behavior
  • Recent (past three months) initiation of psychotropic medication or psychotherapy, or recent change in psychotropic medication treatment
  • Current DSM-IV diagnosis of drug (other than nicotine) dependence, or lifetime diagnosis of opioid dependence
  • DSM-IV alcohol dependence diagnosis judged clinically severe, history or present evidence of significant alcohol withdrawal symptoms, or recurrent use of alcohol to alleviate withdrawal
  • Regular use of opioids in the past month
  • History of hypersensitivity to NTX
  • Considered by study physician not to be suitable for receipt of an investigational drug
  • Likely to require treatment with opiate pain medication during the course of the study

Sites / Locations

  • Research Foundation for Mental Hygiene, Columbia Addiction Services and Psychotherapy Intervention Research, 3 Columbus Circle, Suite 1404

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy

Placebo combined with Modified Behavioral Self-Control Psychotherapy

Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy

Placebo + Brief Behavioral Compliance Enhancement Therapy

Outcomes

Primary Outcome Measures

Quantity of alcohol use
Frequency of binge drinking

Secondary Outcome Measures

Frequency of HIV risk behavior

Full Information

First Posted
March 6, 2007
Last Updated
April 30, 2013
Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00444418
Brief Title
Medication and Counseling for Controlled Drinking (Project SMART)
Official Title
Naltrexone and CBT for Problem-drinking MSM
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to study the effectiveness of medication and specialized psychotherapy in helping gay and bisexual men who do not want to quit drinking learn how to reduce their drinking to healthier levels. More information on the study is available at www.projectsmartnyc.org.
Detailed Description
Problem drinking gay and bisexual men who try to quit drinking are at risk for relapse to heavy or problematic drinking because their social lives and social outlets are often strongly associated with alcohol. These men are most receptive to interventions focused on moderation of drinking rather than abstinence. However moderation-oriented cognitive-behavior therapy (CBT) and naltrexone (NTX) are both well established treatments for problem drinkers who wish to moderate, rather than stop, drinking. Research suggests that combining these treatments may enhance their efficacy. This study combines moderation-oriented CBT with NTX in the treatment of problem drinking gay and bisexual men, who do not wish to abstain from alcohol, to evaluate their efficacy alone and in combination. We also propose to utilize new data collection technology, Interactive Voice Response, to collect data on daily relations among drinking, sexual behavior and psychological variables thought to mediate treatment response. Our objectives are to evaluate the efficacy of 12 weeks of randomly assigned treatment, with 100 mg of NTX or placebo, combined with brief supportive therapy or modified, behavioral self-control therapy specifically tailored to gay/bisexual men; to evaluate conditional relationships between heavy drinking and likelihood of HIV risk behavior; and to evaluate daily associations among mood, craving, self-efficacy, motivation, and drinking. Assessments will include baseline, 3, 6, & 9 month follow-up. A substudy of the treatment trial will be conducted to collect and bank samples from blood for research aimed at associating naturally occurring differences in DNA with patient response to NTX, and with potential mediational mechanisms of action of NTX. Information gathered on genes or gene products may be used in conjunction with data on clinical and psychological factors obtained as part of the clinical trial to evaluate relationships among genetic variants, drug effects, and mechanisms of treatment response. Patients will be asked to give a blood sample at Week 0 of the clinical trial for the purpose of carrying out genetic research.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Keywords
Drinking, Alcohol problems, Alcoholism, Gay men, Bisexual men, Moderation-oriented treatment, Controlled drinking, Non-abstinence based treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
Arm Title
2
Arm Type
Experimental
Arm Description
Placebo combined with Modified Behavioral Self-Control Psychotherapy
Arm Title
3
Arm Type
Experimental
Arm Description
Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
Arm Title
4
Arm Type
Placebo Comparator
Arm Description
Placebo + Brief Behavioral Compliance Enhancement Therapy
Intervention Type
Drug
Intervention Name(s)
Naltrexone
Other Intervention Name(s)
Naloxone, Revia, Depade
Intervention Description
Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Modified Behavioral Self-Control Psychotherapy
Intervention Description
Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
Intervention Type
Behavioral
Intervention Name(s)
Brief Behavioral Compliance Enhancement Therapy
Intervention Description
Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
Primary Outcome Measure Information:
Title
Quantity of alcohol use
Time Frame
9 months
Title
Frequency of binge drinking
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Frequency of HIV risk behavior
Time Frame
9 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males 18-65 years old Currently sexually active with other men Report drinking at levels substantially in excess of established guidelines for non-hazardous drinking Willing to reduce drinking to non-hazardous levels English literate (8th grade level) Exclusion Criteria: Current physical disease or condition making participant inappropriate for a medication trial, including total bilirubin elevation >110%, AST or ALT elevations >300%. History of serious psychiatric illness (psychotic disorder, bipolar disorder, or psychiatric illness requiring hospitalization), current psychiatric illness (such as major depression or post-traumatic stress disorder) that requires treatment but that is currently untreated, or serious risk of suicidal or violent behavior Recent (past three months) initiation of psychotropic medication or psychotherapy, or recent change in psychotropic medication treatment Current DSM-IV diagnosis of drug (other than nicotine) dependence, or lifetime diagnosis of opioid dependence DSM-IV alcohol dependence diagnosis judged clinically severe, history or present evidence of significant alcohol withdrawal symptoms, or recurrent use of alcohol to alleviate withdrawal Regular use of opioids in the past month History of hypersensitivity to NTX Considered by study physician not to be suitable for receipt of an investigational drug Likely to require treatment with opiate pain medication during the course of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jon Morgenstern, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Foundation for Mental Hygiene, Columbia Addiction Services and Psychotherapy Intervention Research, 3 Columbus Circle, Suite 1404
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Medication and Counseling for Controlled Drinking (Project SMART)

We'll reach out to this number within 24 hrs